New Oral Drug Slows Alzheimer's and Lewy Body Dementia

Millions of families watching loved ones slip away to dementia may finally have reason for hope.

Cognition Therapeutics is developing zervimesine, an investigational once-daily pill that targets brain damage before it becomes permanent. Unlike complex treatment regimens requiring injections or infusions, patients simply take this oral medication at home.

The drug works by stopping toxic proteins called oligomers from destroying the connections between brain cells. CEO Lisa Ricciardi explains it simply: these toxic proteins gather at synapses where brain cells communicate, and zervimesine clears them out before neurons die.

In clinical studies, the results stunned researchers. Alzheimer's patients taking zervimesine showed significantly slower disease progression. For patients with dementia with Lewy bodies (DLB), the improvements were even more dramatic.

DLB patients experienced substantial reductions in twelve different neuropsychiatric symptoms. The drug showed particularly strong effects against psychosis, including the terrifying hallucinations and delusions that often force families to move loved ones into institutional care.

One caregiver described keeping a walker by the bed because her husband never knew each morning whether he'd be able to walk normally. Another told Ricciardi about taking her husband to the doctor during a good moment, only to have the physician dismiss her concerns while she lived daily with his severe fluctuations.

Currently, DLB affects over one million Americans, yet most people have never heard of it. The disease costs more to treat than Alzheimer's because patients fall frequently, experience Parkinsonian symptoms, and end up in emergency rooms repeatedly.

Getting diagnosed takes an average of seven doctor appointments across three specialists over eighteen months. Many patients wait months just to see a neurologist, then months more for testing.

Why This Inspires

Right now, patients facing these devastating diseases have almost no approved treatment options. For DLB specifically, there are none at all.

Cognition is working closely with the FDA to fast-track development and gather real-world evidence about how the therapy works in practice. The company's focus on an oral medication means the treatment could reach far more patients than complex therapies requiring specialized medical facilities.

For the six million Americans living with Alzheimer's (projected to reach 30 million) and the severely underserved DLB community, this represents the first real chance to slow progression and preserve quality of life.

The simplicity matters too. An oral pill means caregivers can manage treatment at home, reducing the overwhelming burden these families carry while giving patients more time being themselves.